Sponsor NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.

Your donation will directly support this research project led by Dr. William G Wierda at City of Hope Comprehensive Cancer Center.

Support This Research

Support this research directly through verified donation platforms:

Donate via City Donate via LLS

Direct Support: All donations are processed securely through verified donation portals. When donating through the institution, specify that your gift supports leukemia research. LLS funds support leukemia research programs nationwide. 100% of your contribution advances leukemia research.

About This Project

The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton's tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors has emerged as an effective chemotherapy-free option for patients with previously untreated or relapsed/refractory CLL/SLL. Undetectable minimal residual disease after the end of treatment is emerging as an important predictor of progression-free and overall survival for patients treated with fixed-duration BCL-2 inhibitor-based treatment. These NCCN Guidelines Insights discuss the updates to the NCCN Guidelines for CLL/SLL specific to the use of chemotherapy-free treatment options for patients with treatment-naïve and relapsed/refractory disease.

Your Impact

By sponsoring this research project, you're directly contributing to advancing leukemia treatment and finding cures. Every dollar helps researchers conduct critical studies, purchase equipment, and support clinical trials that can save lives.

Back to Project Details